There is a variation in platelet function between normal individuals and this function is consistent within the same individual over time.
Introduction
Most platelets are transfused prophylactically, on the basis of platelet count, to reduce the risk of bleeding in patients who have developed thrombocytopenia as a result of treatment for haematological malignancies 1 .
Blood Services ensure the safety and efficacy of platelets for transfusion through validation of new processes for their collection, production and storage, and compliance with regulatory standards. However, little attention has been paid to the effect of donor-related variation in the donated material on patient outcomes. This is particularly relevant to platelets collected by apheresis (derived from single donors), where platelet dysfunction in the donor will have a larger effect than those derived from a pool of four or more whole blood donations.
Unlike drugs, that can be produced to uniform potency, the composition of platelet concentrates for the prevention or treatment of bleeding varies, mainly due to natural variation in haematological traits between donors. Platelet function is highly variable between individuals, but for a given individual is highly consistent over time 2 . These observations together with those in twins 3 , suggests that platelet function is to a large extent a heritable trait. Consequently, there is great interest in how such variation may relate to an individual's risk of thrombosis or bleeding and in tailoring of pharmacological interventions to reduce this risk. We have shown that inherent variation in platelet responsiveness to agonists assessed by flow cytometry is to a large extent genetically controlled, by employing methods that assess two well characterised but distinct platelet signalling pathways known to be important in platelet activation after atherosclerotic plaque rupture, and that provide information on both platelet receptor activation and degranulation 4 . We have identified 24 genes that show an association between platelet responsiveness and sequence variation and demonstrated that platelet responsiveness of a donor at the extremes of the distribution of responses (high or low) is reproducible over time 4, 5 and that donors with highly responsive platelets are more likely to produce a unit of platelets containing a higher level of activated platelets 6 .
Whether increased activation that occurs during storage of platelets reduces platelet survival once transfused is unclear. Data from animals models is mixed -some suggest that platelet activation is related to platelet clearance 7 whereas others suggest that this is not the case 8, 9 . In humans, several studies have suggested that increased platelet activation in platelet concentrates might be associated with reduced survival following infusion to healthy subjects 10, 11 , whereas others have failed to observe such a relationship 12 .
There is increasing evidence to suggest that phenotypic and proteomic changes that occur during the storage of red cells and platelets for transfusion may in part be determined by the genotype of the donor [13] [14] [15] . These observations and others have led to an increased international focus on the role of the donor in the quality of red cells and platelets for transfusion. Reduced costs and ease of genotyping now make large scale testing of donors a reality. It is therefore important to understand whether genetic variation in platelet function at the point of donation and/or on subsequent storage translates into clinically relevant outcomes for recipients of platelets.
This is the first study in the literature to examine this question.
We conducted a trial in patients receiving platelets for prophylaxis to assess whether differences in platelet function in the donor population affect the clinical outcome from platelet transfusion. To maximise the likelihood of observing a difference between groups, we selected donors with platelet responsiveness at the extreme ends of the distribution (high or low responders). We hypothesised that platelets derived from high responder donors would be cleared more rapidly from the circulation than those from low responder donors, leading to lower platelet count increments following transfusion, and potentially a shortening of the time until the next platelet transfusion was required.
Methods

Study design
We conducted a parallel-group, double-blinded, semi-randomised trial at a single centre in the UK -the Platelet
Responsiveness and Outcome from Platelet Transfusion (PROmPT) trial. Patients were randomised to receive a single platelet transfusion from either a high or low responder donor. Since it was possible that platelets from high or low responder donors may not differ from each other, but that either might differ from those from donors of average responsiveness, we concurrently enrolled a group of 30 patients that received platelets from unselected donors for comparison (referred to as unselected units). Participants, treating clinicians, those assessing outcomes and analysing data were blinded to treatment group throughout. Randomisation was performed using unstratified permuted blocks via an on-line randomisation service (www.sealedenvelope.com)
by randomisation coordinators who were not part of the trial personnel involved in the enrolment, treatment or measurement of outcomes. The protocol included a pre-specified interim analysis after 20 patients presented for randomisation, as we predicted that insufficient platelet availability might result in an unacceptably low percentage of enrolled patients being randomised. The study protocol specified that in such circumstances an alternative treatment allocation procedure would be followed, resulting in a semi-randomised study: when donor platelet units from both high and low responders were available, patients would be randomised to receive either, but if only one type of platelet unit were available (i.e. from either a high or low responder) the patient would receive that unit (non-randomised). Although the allocation was not randomised in this circumstance, blinding was maintained. If neither were available then patients received a suitable platelet unit from an unselected donor. The full study protocol is publically available 16 .
Participants a) Donors
We previously established a cohort of 506 donors whose platelets were tested by flow cytometry for responsiveness to two agonists (collagen-related peptide-XL or ADP) each with two measures of response (fibrinogen binding or P-selectin expression) resulting in four endpoints 4 . To provide sufficient donors for this study we increased this cohort to 956 by testing an additional 450 donors using the same methods. To determine the platelet responsiveness phenotype, the percentage positive (PP) platelets for each of the four endpoints was transformed to the logit scale, that is, log(PP/(100-PP)) and then a multiple linear regression model applied with the date of sample testing as a continuous predictor. To combine the data into one overall measure of platelet response and thus assign the donor to a high or low category, the data from each of the four endpoints was transformed so that the data from each output occupied the same range and distribution as described previously Approval for the study was granted from the Hertfordshire Research Ethics Committee (Reference 11/EE/0227).
Procedures
Donors for the study fulfilled all requirements for platelet donation according to national guidelines 17 .
Leucocyte-depleted platelets were collected by apheresis using a single type of collection device for the entire study duration (Trima Accel, Terumo BCT, Lakewood, Co, USA) and stored in plasma for up to 5 days from donation. Patients that were likely to become thrombocytopenic and require a prophylactic platelet transfusion were enrolled by their clinical care team. The decision to transfuse was made by the clinician caring for the patient, usually when the platelet count fell below 10 x10 9 /L according to local and national guidelines. Patients received a single unit of platelets and were followed up for 5 days or until their next platelet transfusion.
Platelets were matched for ABO and RhD blood group according to local guidelines. The threshold for red cell transfusion in the absence of bleeding was 90g/L haemoglobin. Blood samples were taken on the day of transfusion, and 10-90 minutes and 12-36 hours after transfusion. A full blood count was made on samples anticoagulated with EDTA using a haematology analyser to measure platelet count (LH750, Beckman Coulter, High Wycombe, UK). Bleeding symptoms were recorded on the day of transfusion and daily thereafter by the clinical team and by validated patient self-assessment 18 . Clinician and patient self-assessment were made for days when patients were in hospital, but patient self-assessment only for periods of follow up when patients were at home. Bleeding was graded according to a modified WHO system by the use of a computer generated algorithm. In this, the most commonly used method of assessing bleeding in platelet transfusion trials, bleeding is categorised as grade 1 (mild), grade 2 (moderate, not usually requiring red cells transfusion), grade 3 (severe, requiring red cell transfusion) and grade 4 (debilitating or life-threatening). In accordance with a recent trial of platelet transfusion that required assessment of bleeding 19 , two types of grade 1 bleeding (spreading or generalised petechiae or a nose bleed lasting more than 30 minutes) were classified as grade 2 for this study since these may be considered clinically significant in patients with thrombocytopenia and regarded by many treating clinicians as a trigger for platelet transfusion.
Outcomes
The primary outcome was the platelet count increment (CI) 1 hour (10-90 minutes) following transfusion, i.e.
the difference between platelet count before and after transfusion. Secondary outcomes were the platelet CI at ). Bleeding assessed by study clinician or patient self-assessment were considered as separate outcomes. Data on adverse events were collected according to standard definitions used in the UK Serious Hazards of Transfusion Haemovigilance scheme. Events which were judged to be expected and as a result of the patient's underlying diagnosis were not reported as serious adverse events (SAEs) but were logged as adverse events. The rationale for choice of endpoints can be found in the full study protocol 16 .
Statistical Analysis
The required sample size was calculated based on the difference in the platelet count increment (primary outcome) following transfusion between patients receiving platelets from high or low responder donors. Interim data from another clinical study of platelets ongoing in our organisation at the time and since reported for the same measure 20 gave a standard deviation of 11.5x10 9 /L (at 12-36 hours, from 65 patients and 95 transfusions).
Based on 80% power, a 5% significance level, and a presumed 10% dropout rate, 100 patients (50 in each group) would be required to detect a mean difference of 7x10 9 /L between the two groups.
A secondary set of analyses included patients who received units from unselected donors, in order to assess whether units from high or low responder donors differed to those from donors not at the extremes of the distribution. Recruiting 30 patients who received platelets from unselected donors allowed calculation of a 95%
confidence interval for the difference in platelet increments between a treatment group and the unselected group to within +/-2.5 (i.e. the width of the confidence interval will be 5). As some of the patients that received a transfusion from an unselected donor also received a transfusion from a high or low-responder donor, this also increased the precision of estimates.
All analyses were by intention-to-treat and all patients allocated to receive a trial unit were included in the analysis, regardless of whether they were randomised to receive that unit, or not except for two patients in the unselected group who received a pooled platelet concentrate rather than apheresis and were excluded from analysis. Analyses were two-sided, and the significance level was 5%. Platelet count increments at 1 and 24
hours were analysed using a mixed-effects linear regression model with a treatment-time interaction. In order to increase power, the model was adjusted for body surface area, platelet dose, and age of platelet unit, factors known to affect these outcomes. All patients with an observed platelet count increment at either 1 or 24 hours
were included in the analysis. Further details of the regression models used can be found in the supplementary materials and methods for dealing with missing data are given in the study Statistical Analysis Plan 21 .
An independent data monitoring committee reviewed patient safety and the results of the interim data analysis. 
Results
The interim analysis took place after 21 patients had presented for randomisation, of which only 9 had been successfully randomised, predominantly due to insufficient supply of trial units. Therefore, as pre-specified in the protocol, the study became semi-randomised at that point.
Of 428 patients screened, 252 consented to be part of the study (Figure 1 ). Of the 252 patients consented, 137
were not allocated to receive a transfusion as there was either no suitable platelet unit available or the patient had a temporary exclusion criterion. One hundred patients were allocated to receive a trial unit: 49 from a high responder donor (23 randomised, 26 non-randomised) and 51 from a low responder donor (24 randomised, 27 non-randomised). One patient due to receive platelets from a donor in the low responder group withdrew consent prior to transfusion. Therefore, 49/49 patients in the high responder group and 50/51 in the low responder group received their allocated trial unit. Thirty patients consented and were assigned to receive a transfusion from an unselected donor. Two of the 30 patients received a pooled platelet concentrate rather than apheresis and were excluded from analysis. In total, 15 patients received a transfusion from both an unselected donor and either a high or low-responder donor.
Baseline characteristics were well matched between study groups (Table 1) . Platelets for the trial were derived from 15 high responder and 16 low responder donors. Platelet units that were ABO identical to that of the donor were received by 96% of patients, and 98% of trial units transfused were irradiated. All RhD negative patients received RhD negative units.
The platelet count increment at 1 hour (the primary endpoint) was available for 90% of patients in the low responder group and 100% of patients in the high responder group. For the 24 hour platelet count increment, these values were 90% and 96% respectively. Assessment of bleeding symptoms by a clinician was made for for 92% and 94% of patients respectively. Data on red cell transfusions and time to next platelet transfusion were collected on 100% of patients.
Results are shown in Tables 2 and 3 Table 3 . In addition, there was no significant difference in any of the outcomes measured between high or low responder groups and patients that received platelets from unselected donors (Tables 2 &   3 ).
There was one febrile transfusion reaction reported in the low responder arm of the trial. This was initially reported as a SAE, but on further analysis did not meet criteria as the patient recovered rapidly with no increased duration of hospitalisation. There were no other SAEs.
Discussion
In the first controlled trial to assess whether differences in the level of platelet responsiveness in the donor population affect clinical outcome, we have shown that the outcome from prophylactic platelet transfusion in haematology patients does not differ whether the donor of the platelets has very low or highly responsive platelets to agonists in vitro.
The results from our study add to those conducted in healthy subjects and suggest that the ability of platelets to survive in the circulation following transfusion to patients is not related to how responsive the platelets of the donor are. Since the main indication to transfuse platelets is to prevent bleeding, and there is a poor correlation between bleeding risk and platelet count increments in thrombocytopenic patients we also assessed bleeding according to the WHO grading system, the most commonly used method of assessing bleeding in platelet transfusion trials. We also collected data on the number of red cell transfusions and time to next platelet transfusion as surrogates for bleeding. There was no significant difference between groups in any of these endpoints. Although the study was not powered with bleeding as the primary endpoint, these data indicate that in addition to there being no difference in the survival of platelets following transfusion between groups, the ability of platelets to prevent bleeding was also not different. The percentage of patients experiencing grade 2 or higher bleeding symptoms was lower in this study (18-25%) compared with other recent prophylactic platelet trials such as TOPPS (43%) and PLADO (70%). We attribute this to the strict exclusion criteria in this study, especially temporary deferral for fever, and because patients were only studied for one platelet transfusion.
Only two other clinical studies have attempted to address whether differences in the functionality of platelets might influence outcome from platelet transfusion. An observational study measuring levels of P-selectin, a marker of platelet activation, in platelet concentrates suggested that lower 1 hour count increments were observed with increasing levels of platelet activation 22 . However, the study was too small (eight patients) to draw any conclusions. In another observational study, transfusions to 40 children were retrospectively categorised into two groups (high and low) based on the immature platelet fraction (IPF) of the platelet concentrate transfused 23 . The IPF is a parameter reported by some haematology analysers that indicates the proportion of platelets that are reticulocytes, those platelets most recently formed 24 . Those receiving platelets from the 'high' group received fewer platelet transfusions, and had fewer bleeding episodes, although the method of assessing bleeding in the study is unclear. In our study we observed a higher IPF in the whole blood of high-responder donors, but following transfusion there was no difference in the IPF measured between patients receiving platelets from high or low-responder donors (data not shown). This discrepancy could be due to preferential removal of sub-populations of platelets by either the apheresis device or transfusion set.
The data from our study are intriguing, indicating that differences identified by laboratory testing of measures such as platelet responsiveness in platelet donors prior to donation do not translate to differences in clinical outcome from platelet transfusion. It is therefore essential that major changes to platelet production that might affect their function undergo clinical assessment prior to introduction, rather than rely solely on laboratory data.
In addition, there is insufficient evidence to recommend that platelet donors be selected on the basis of platelet function. Therefore, our data support the current policy employed by blood services internationally of not assessing platelet function in apheresis donors prior to donation.
The strengths of our study include the high level of adherence to protocol and little loss to follow up or missing data. Although approximately 50% of patients were not randomised, the number of transfusions from high or low responder donors was almost equal, the baseline characteristics of patients between groups were similar, and the blinding of the study meant that study personnel could not bias outcomes between groups. Limitations of our study include that patients received a single trial transfusion only. Data from trials of pathogen inactivated platelets have shown that differences between control and treated units are more pronounced with increasing number of platelet transfusions 25 and we therefore cannot exclude that differences between groups in our study may have been observed if patients received multiple transfusions. We also cannot exclude the potential influence of previous non-trial transfusions on the outcomes measured.
An important limitation to the generalisability of our data are that we assessed stable non-bleeding patients requiring platelets for prophylaxis. We cannot extrapolate these data to patients actively bleeding at the time of transfusion, where the immediate haemostatic effectiveness of platelets might be more important than the ability to remain in the circulation. It is conceivable that platelets from high responder donors could be the product of choice for bleeding patients, but this can only be elucidated by further research. The role of genetic factors in determining aspects of platelet function that may be important in disease states as well as platelet storage and the outcome from transfusion warrants further study. * taken from a linear mixed-effects model on both 1 and 24 hour time-points with the unselected group as reference, adjusted for body surface area (BSA), the platelet dose transfused, age of platelets transfused. ** taken from a linear mixed-effects model on both 1 and 24 hour time-points with the unselected group as reference, adjusted for age of platelets transfused. † taken from a linear mixed-effects model on both 1 and 24 hour time-points with the high responder group as reference, adjusted for BSA, the platelet dose transfused, age of platelets transfused. † † taken from a linear mixed-effects model on both 1 and 24 hour time-points with the high responder group as reference, adjusted for age of platelets transfused. 
